

## RESEARCH ARTICLE

## Open Access

# Production of recombinant human annexin V by fed-batch cultivation

Laura S Marder<sup>1,2†</sup>, Juleane Lunardi<sup>2,4†</sup>, Gaby Renard<sup>4</sup>, Diana C Rostirolla<sup>1,3</sup>, Guilherme O Petersen<sup>1,2,4</sup>, José E S Nunes<sup>4</sup>, Ana Paula D de Souza<sup>5</sup>, Ana Christina de O Dias<sup>4</sup>, Joicelei M Chies<sup>4</sup>, Luiz A Basso<sup>1,2,3</sup>, Diógenes S Santos<sup>1,2,3</sup> and Cristiano V Bizarro<sup>1,2\*</sup>

## Abstract

**Background:** Annexin V, a 35.8 kDa intracellular protein, is a  $\text{Ca}^{+2}$ - dependent phospholipid binding protein with high affinity to phosphatidylserine (PS), which is a well-known hallmark of apoptosis. Annexin V is a sensitive probe for PS exposure upon the cell membrane, and used for detection of apoptotic cells both *in vivo* and *in vitro*. Large-scale production of recombinant human annexin V is worth optimization, because of its wide use in nuclear medicine, radiolabeled with <sup>99m</sup>Tc, for the evaluation of cancer chemotherapy treatments, and its use in identification of apoptotic cells in histologic studies. Here we describe the high-yield production of a tag-free version of human annexin V recombinant protein by linear fed-batch cultivation in a bioreactor.

**Results:** We cloned the human *ANXA5* coding sequence into the pET-30a (+) expression vector and expressed rhANXA5 in batch and fed-batch cultures. Using *E. coli* BL21 (DE3) in a semi-defined medium at 37°C, pH 7 in fed-batch cultures, we obtained a 45-fold increase in biomass production, respective to shaker cultivations. We developed a single-step protocol for rhANXA5 purification using a strong anion-exchange column (MonoQ HR16/10). Using these procedures, we obtained 28.5 mg of homogeneous, nontagged and biologically functional human annexin V recombinant protein from 3 g wet weight of bacterial cells from bioreactor cultures. The identity and molecular mass of rhANXA5 was confirmed by mass spectrometry. Moreover, the purified rhANXA5 protein was functionally evaluated in a FITC-annexin V binding experiment and the results demonstrated that rhANXA5 detected apoptotic cells similarly to a commercial kit.

**Conclusions:** We describe a new fed-batch method to produce recombinant human annexin V in large scale, which may expand the commercial utilities for rhANXAV to applications such as *in vivo* imaging studies.

**Keywords:** Recombinant human annexin v, Fed-batch cultivation, Large-scale, Apoptosis detection

## Background

Annexin V, formerly known as human placental anticoagulation protein, is a member of a family of calcium-dependent phospholipid binding proteins [1] that binds preferentially to phosphatidylserine (PS), a negatively charged phospholipid highly enriched in the inner leaflet of plasma membranes [2]. Annexin V shows minimal capacity to bind phospholipids that are constitutively present

in the outer leaflet of plasma membranes, such as phosphatidylcholine and sphingomyelin [1]. During the early stages of apoptosis, cells expose PS on the surface, which is specifically recognized by phagocytic cells [3]. The exposed PS residues can be bound selectively by annexin V with nanomolar to picomolar affinity [4,5]. Because of the role of apoptosis in the pathophysiology of many diseases, there is a wide range of current and potentially new applications for annexin V as an apoptotic marker in clinical diagnosis [6]. Staining cells simultaneously with annexin V labeled with the fluorochrome fluorescein isothiocyanate (FITC) and the non-vital dye propidium iodide (PI) allows the discrimination among intact cells (FITC<sup>-</sup>/PI<sup>-</sup>) early apoptotic cells (FITC<sup>+</sup>/PI<sup>-</sup>) and late

\* Correspondence: [cristiano.bizarro@pucrs.br](mailto:cristiano.bizarro@pucrs.br)

†Equal contributors

<sup>1</sup>Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga 6681, 90619-900 Porto Alegre, Brazil

<sup>2</sup>Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre 90619-900, Brazil

Full list of author information is available at the end of the article

apoptotic or necrotic cells (FITC<sup>+</sup>/PI<sup>+</sup>) [7]. Moreover, recombinant human annexin V (rhANXA5) serves as an important *in vivo* diagnostic tool when labeled with different radionuclides, such as iodine-123 (<sup>123</sup>I) and the metastable isotope technetium-99 (<sup>99m</sup>Tc) providing a broad range of imaging applications in apoptosis research, as single-photon emission computed tomography and autoradiography to positron emission tomography [8]. In nuclear medicine, annexin V radiolabeled with <sup>99m</sup>Tc or <sup>123</sup>I is used to evaluate the efficacy of cancer therapy and disease progression or regression [9].

Because of its widespread use as a diagnostic tool, rhANXA5 is commercially produced in microorganisms such as *Escherichia coli* using recombinant DNA techniques [10-13]. To produce rhANXA5 in large scale in this study, we used *E. coli*, the most commonly used host for recombinant protein production [14]. In shake flask cultures, all components are added at the start of the cultivation, without the need to monitor or control any parameter such as pH or the level of dissolved oxygen, leading to slow growth and low recombinant protein production [15]. High cell-density culture techniques have been developed to improve productivity and to provide advantages such as reduced culture volume, enhanced downstream processing, reduced wastewater, lower production costs and reduced investment in equipment [14]. Fed-batch cultivation is an effective and simple method [16], allowing substantial concentrations of glucose, an inexpensive and readily usable carbon and energy source [17]. To our knowledge, there is currently no protocol available for a bioreactor-based, large-scale production of rhANXA5.

In this work, we describe a procedure for the production of 28.5 mg of homogeneous, nontagged rhANXA5 from 3 g wet weight of bacterial cells from bioreactor cultures. The identity and absence of host contaminants in purified rhANXA5 was confirmed by LC-MS/MS peptide mapping experiments. The molecular mass determination of intact rhANXA5 confirmed the integrity of the purified protein. Additionally, the produced rhANXA5 protein was shown to be functional in a bioassay for *in vitro* apoptosis/necrosis detection, in which it performed similarly to a commercially available kit.

## Results and discussion

### Cloning and expression of rhANXA5

The gene encoding human Annexin V, ANXA5, is located on human chromosome 4q27 locus and spans a region of DNA 29 kb in length containing 13 exons and 12 introns. ANXA5 encodes a 35.8 kDa protein of 320 amino acid residues in length which is translated from a single mature transcript of approximately 1.6 kb [18]. The human ANXA5 coding sequence was subcloned into the pET-30a (+) expression vector to generate the recombinant pET-30a (+)::ANXA5 plasmid. Both the sequence and the absence of

PCR-introduced mutations in the ANXA5 coding sequence were confirmed by automated sequencing.

The BL21 (DE3) and C41 (DE3) *E. coli* strains were transformed with the pET-30a (+)::ANXA5 construct by electroporation. The expression profiles were tested in lysogeny broth (LB) and in our semi-defined (SD) medium. The best results of soluble recombinant protein production from shaker cultivation were obtained using the BL21 (DE3) strain in SD medium induced with 1 mM IPTG at 37°C (Additional file 1: Figures S1 and Figure S2).

### Bioreactor cultivation


The best growth conditions found in shaker cultivations were applied to the bioreactor batch and fed-batch cultures. We employed our SD medium and a temperature of 37°C in all experiments.

Transformed BL21 (DE3) *E. coli* was grown from a master cell bank (MCB) under batch cultivation in 1 L of SD medium at 37°C monitoring glucose consumption. Within 4 h, glucose was depleted from media, indicating this was the right time to start feeding. We compared DO-stat, pH-stat and linear ascending feeding strategies in uninduced cultures. A biomass concentration of 26.01 g (DCW) L<sup>-1</sup> was attained in an uninduced culture using the linear ascending feeding profile [17]. Lower values for biomass concentration were obtained using DO-stat (20.15 g (DCW) L<sup>-1</sup>) or pH-stat (11.59 g (DCW) L<sup>-1</sup>) feeding strategies. Therefore, we selected the linear ascending feeding strategy for further fed-batch cultivations.


After 4 h of batch cultivation without feeding, the biomass concentration reached 4.71 g (DCW) L<sup>-1</sup> (n = 4, SD = 0.6). We induced rhANXA5 expression in fed-batch cultivations with linear ascending feeding by adding IPTG to a final concentration of 1 mM. From three independent fermentations, we obtained a mean value of 27.48 g (DCW) L<sup>-1</sup> (SD = 1.96) for the biomass concentration and a total protein content of 4.8 g L<sup>-1</sup> (Figure 1). In contrast, we obtained a biomass concentration of 0.615 g (DCW) L<sup>-1</sup> in shaker cultivation (OD<sub>600nm</sub> = 1.84) after 6 h of culture. This represents a 45-fold increase in biomass concentration.

In an independent bioreactor cultivation, we performed densitometric analysis of culture samples (in triplicate) to calculate the product yield (g (rhANXA5) L<sup>-1</sup>), the productivity (g (rhANXA5) L<sup>-1</sup> h<sup>-1</sup>) and the specific yield (g (rhANXA5) g (DCW)<sup>-1</sup>). rhANXA5 corresponded to 40.6% (mean value) of the total protein content (n = 3, SD = 0.03) (Additional file 1: Figure S4). Therefore, we obtained a product yield of 1.95 g (rhANXA5) L<sup>-1</sup> of culture medium, a specific yield of 0.0715 g (rhANXA5) g (DCW)<sup>-1</sup> and a productivity of 0.065 g (rhANXA5) L<sup>-1</sup> h<sup>-1</sup>, considering the entire fermentation period (30 h).

Moreover, we can consider the entire procedure, from bioreactor cultivation to protein purification, and calculate



**Figure 1** SDS-PAGE analysis of rhANXA5 expression in fed-batch cultivations. Recombinant *E. coli* BL21(DE3) cells were cultivated in semi-defined (SD) media for 30 h in fed-batch cultivations. Feeding started 4 h after the beginning of batch cultivation and rhANXA5 expression was induced after 18 h of cultivation by the addition of 1 mM IPTG to the cultures. M: Thermo Scientific™ Unstained Protein MW Marker; lane 1: sample collected immediately before IPTG induction (18 h culture); lanes 2–7: samples collected after IPTG induction from 20 h (lane 2), 22 h (lane 3), 24 h (lane 4), 26 h (lane 5), 28 h (lane 6), and 30 h (lane 7) cultures.



**Figure 2** SDS-PAGE analysis of rhANXA5 purification steps. SDS-PAGE (12%) analysis of fractions from different steps of rhANXA5 purification. Each sample lane contains 8  $\mu$ g of total protein. M corresponds to Thermo Scientific™ Unstained Protein MW Marker; lane 1: cells suspended in buffer A (50 mM Tris-HCl, pH 7.2, 10 mM CaCl<sub>2</sub>) with no previous centrifugation step; lane 2: supernatant of cells in buffer A after sonication and centrifugation (for 20 min, 24,400  $\times$  g, 4°C); lane 3: cell pellet from the previous centrifugation suspended in buffer B (50 mM Tris-HCl, pH 7.2, 20 mM EDTA); lane 4: suspension from previous step dialyzed against 2 L of 20 mM Tris-HCl, pH 8.0 for 3 times, overnight in the first step, followed by two steps of dialysis 2 h each; lane 5: supernatant after centrifugation of dialyzed sample (for 30 min, 24,400  $\times$  g, 4°C); lane 6: homogeneous preparation of annexin V eluted from the Mono Q column.

the yield and productivity of homogeneous rhANXA5. From four independent purifications, we obtained a mean value of 28.5 mg of purified rhANXA5 from 3 g wet weight of cells ( $n = 4$ ,  $SD = 6.7$ ). In terms of volumetric yield, we obtained (mean value) 0.983 g (purified rhANXA5)  $L^{-1}$  ( $n = 4$ ,  $SD = 0.23$ ). The productivity over the entire fermentation (30 h) was 0.0361 g (purified rhANXA5)  $L^{-1} h^{-1}$  ( $n = 4$ ,  $SD = 0.0084$ ).

#### Purification

The overexpressed protein was purified by a single-step protocol consisting of a strong anion-exchange column (MonoQ HR16/10). Figure 2 shows the steps of rhANXA5 purification. The target protein eluted at approximately 190 mM of NaCl from a MonoQ HR 16/10 column (Additional file 1: Figure S3). The eluted protein was pooled and dialyzed against HEPES 100 mM NaCl pH 7.2, concentrated using an AMICON ultra-filtration membrane and stored at  $-80^{\circ}C$  in 1 mL aliquots. This purification protocol yielded 28.5 mg of purified rhANXA5 from 3 g wet weight of cells ( $n = 4$ ,  $SD = 6.7$ ).

#### rhANXA5 identification by mass spectrometry

Homogeneous rhANXA5 samples were desalted and digested with trypsin, and the peptide mixtures were analyzed in LC-MS/MS peptide mapping experiments. A total of 320 spectra were identified with 29 different peptides derived from rhANXA5 protein. These peptides covered 80% of the rhANXA5 sequence.


#### Determination of rhANXA5 molecular mass

The spectra of intact rhANXA5 samples were recorded with a linear ion trap analyzer. Peaks spanning charge


states 18+ to 39+ were detected (Figure 3a) and the spectra deconvoluted. We obtained a value of 35,804 Da for the average molecular mass of rhANXA5 (Figure 3b), consistent with the post-translational removal of the N-terminal methionine (theoretical average molecular mass of 35,937 Da with methionine and 35,805 Da without methionine).

#### FITC-annexin V binding test

To test the functional activity of purified rhANXA5, we assayed its ability to detect cells undergoing apoptosis. We treated B16F10 cells with cisplatin to induce apoptosis and after 6 or 12 h, we stained treated cells simultaneously with the non-vital dye PI and with rhANXA5 labeled with the fluorochrome FITC. Double staining allows the discrimination between intact cells (FITC<sup>-</sup>/PI<sup>-</sup>), early apoptotic cells (FITC<sup>+</sup>/PI<sup>-</sup>) and late apoptotic or necrotic cells (FITC<sup>+</sup>/PI<sup>+</sup>) [7]. The ability of FITC-labeled rhANXA5 to detect apoptotic cells was compared with a commercial kit from BD. We performed dose curve experiments with different concentrations of cisplatin and stained treated cells for 6 h (Figure 4a) or 12 h (Figure 4b) after treatment. We obtained similar results using our home-made kit (QuatroG) or the commercial kit at different times after treatment (6 h or 12 h) and concentrations of cisplatin (20, 40, 80 and 160  $\mu$ g/mL), indicating that purified rhANXA5 is functionally active. Dot plot representations



of flow cytometry experiments with cells stained 12 h after treatment clearly show differences in the distribution of FITC/PI cell populations between untreated cells (negative control), cells treated with 40  $\mu\text{g}/\text{mL}$  and cells treated with 160  $\mu\text{g}/\text{mL}$  of cisplatin (Figure 5).



## Conclusions

Fed-batch cultivations represent an alternative to shaker cultivations, allowing control of process variables and improvement on biomass concentration and product yields [15]. A chimeric protein containing the C-terminus of hirudin fused to annexin V was previously expressed in large scale using fed-batch fermentation [19]. However, to the best of our knowledge, this is the first report of a scale up of rhANXA5 production.


Recombinant protein production methods must continuously be improved to meet commercial demands [14,20]. In this work, we produced 28.5 mg of purified recombinant human annexin V from 3 g wet weight of cells ( $n = 4$ ,  $SD = 6.7$ ) obtained in fed-batch cultures induced with IPTG. Moreover, this protocol generated a yield of homogeneous rhANXA5 (mean value) of 0.983 g (purified rhANXA5)  $\text{L}^{-1}$  ( $n = 4$ ,  $SD = 0.23$ ). The productivity over the entire fermentation (30 h) was 0.0361 g (purified rhANXA5)  $\text{L}^{-1} \text{h}^{-1}$  ( $n = 4$ ,  $SD = 0.0084$ ).

rhANXA5 could be commercially distributed to several research groups and to radiopharmaceutical companies. The use of fluorescence-labeled annexin V to identify apoptotic cells is currently limited to histologic and cell-sorting studies performed *in vitro*. Its use for *in vivo* imaging studies is hampered mainly by cost issues. Hence, production in large scale may expand the commercial utilities for rhANXA5, reducing costs and allowing a greater access of the scientific and physician community to this product.

## Methods

### Strains and plasmids

The *E. coli* strains BL21(DE3) and C41(DE3) were purchased from Novagen® (EMD Biosciences, Inc., Madison, WI, USA) and Lucigen Corporation (Middleton, WI, USA), respectively. The PCR-Blunt® cloning vector was



purchased from Invitrogen® (Carlsbad, CA, USA) and the pET-30a (+) expression vector was from Novagen®.

#### Molecular cloning of rANXA5

Oligonucleotides were designed based on the human *ANXA5* coding sequence in the GenBank (accession number: NM\_001154.3) National Institute of Health (NIH) genetic sequence database [18]. Specific primers were designed to contain *NdeI* (forward primer: 5' GCG CAT ATG GCA CAG GTT CTC AGA GGC ACT 3') and *HindIII* (reverse primer: 5' GCG AAG CTT TTA GTC ATC TTC TCC ACA GAG C 3') restriction sites (italics). The human *ANXA5* gene sequence was PCR-amplified from a human blood cDNA sample.

The amplified *ANXA5* coding sequence was cloned into the PCR-Blunt® vector, cleaved with *NdeI* and *HindIII* restriction endonucleases (New England BioLabs®, Ipswich, MA, USA) and subcloned into the pET-30a (+) expression vector, previously digested with the same restriction enzymes, to generate the pET-30a (+)::ANXA5 plasmid. The cloned *ANXA5* sequence was confirmed by automated DNA sequencing.

#### Media preparation

Lysogeny broth (LB) (tryptone, 10 g L<sup>-1</sup>; yeast extract, 5 g L<sup>-1</sup>; NaCl, 10 g L<sup>-1</sup>) was sterilized by autoclaving

(30 min at 121°C). LB medium was used for shake-flask cultivation and for inoculum development of bioreactor cultivations.

Semi-defined medium (SD) [21] was used for shake-flask cultivations as well as fed-batch bioreactor cultivations, as both initial batch and also feeding media (with varied glucose and MgSO<sub>4</sub> concentrations). SD medium contains 0.5 g L<sup>-1</sup> NaCl (a), 1 g L<sup>-1</sup> NH<sub>4</sub>Cl (b), 20 g L<sup>-1</sup> yeast extract (c), 6 g L<sup>-1</sup> Na<sub>2</sub>HPO<sub>4</sub> (d), 3 g L<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> (e), 1 µg L<sup>-1</sup> thiamine (f), 1 mM MgSO<sub>4</sub> (g), 0.1% trace solution (h), and 0.1 mM CaCl<sub>2</sub> (i). For both shake-flask and bioreactor fed-batch cultivations (initial batch culture), SD medium was supplemented with glucose to a final concentration of 5 g L<sup>-1</sup> (j). Components (a) to (e) were assembled and sterilized together by autoclaving (30 min at 121°C), while components (g) to (i) were sterilized separately by autoclaving and added under aseptic conditions. Thiamine solution (f) was filter-sterilized. Trace solution (h) contained 2.8 g L<sup>-1</sup> FeSO<sub>4</sub>, 2 g L<sup>-1</sup> MnCl<sub>2</sub>, 2 g L<sup>-1</sup> CaCl<sub>2</sub>, 0.26 g L<sup>-1</sup> CuCl<sub>2</sub>, and 0.3 g L<sup>-1</sup> ZnSO<sub>4</sub>. For feeding medium in bioreactor cultivations, SD medium was supplemented with glucose (final concentration of 300 g L<sup>-1</sup>) and MgSO<sub>4</sub> (40 mM). To prepare this feeding medium, we mixed equal parts of a 2x concentrated SD medium and a 600 g/L glucose stock solution, both sterilized separately. SD medium used in

bioreactor cultivations was also supplemented with 100  $\mu\text{L}$  of Antifoam 204 (Sigma-Aldrich, São Paulo, SP, Brazil) per liter of culture. Both LB and SD media were supplemented aseptically with filter-sterilized kanamycin to a final concentration of 30  $\mu\text{g mL}^{-1}$ .

#### Shake-flask cultivation

*E. coli* BL21(DE3) and C41(DE3) strains were transformed with the pET-30a (+) vector or the pET-30a (+)::ANXA5 recombinant plasmid by electroporation. Transformant colonies were selected on LB agar plates containing 30  $\mu\text{g mL}^{-1}$  kanamycin [22]. Isolated colonies were selected and grown overnight (at 37°C and 180 rpm) in 5 mL of LB supplemented with 30  $\mu\text{g mL}^{-1}$  kanamycin. To compare the expression profile with different strains (BL21(DE) or C41(DE3)) or media (LB or SD medium), saturated cultures were inoculated in 50 mL of LB or SD medium for shake-flask cultivations and grown at 37°C and 180 rpm to an optical density ( $\text{OD}_{600\text{ nm}}$ ) of 0.4–0.6. At this growth stage, we induced rhANXA5 expression by adding isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. At 3, 6, 9 or 24 h after induction, cells were harvested by centrifugation (11,800  $g$ ) for 30 min at 4°C, and the pellet was stored at –20°C. The expression of the recombinant soluble protein was confirmed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) visualized by Coomassie® Brilliant Blue R-250 staining. For biomass measurements from shake-flask cultures, isolated colonies were selected and grown overnight (at 37°C and 180 rpm) in 10 mL of LB supplemented with 30  $\mu\text{g mL}^{-1}$  kanamycin and inoculated in 500 mL of SD medium. Inoculated cultures were grown (37°C and 180 rpm) to an optical density ( $\text{OD}_{600\text{ nm}}$ ) of 0.4–0.6, rhANXA5 expression was induced by the addition of IPTG to a final concentration of 1 mM, and cells were harvested after 6 h of IPTG induction.

#### Inoculum development for bioreactor cultivation

A master cell bank (MCB) of transformed *E. coli* BL21 (DE3) cells containing the pET-30a (+)::ANXA5 recombinant plasmid was prepared in 50% glycerol and stored at –80°C. For inoculum development, 150  $\mu\text{L}$  of *E. coli* BL21(DE3) MCB cells (stored at –80°C) were grown overnight at 180 rpm and 37°C in 1 L flasks containing 250 mL of LB medium supplemented with 30  $\mu\text{g mL}^{-1}$  kanamycin. The final optical density ( $\text{OD}_{600}$ ) for each pre-inoculum culture was determined spectrophotometrically. For each experiment, we calculated and collected the initial volume of pre-inoculum culture needed to start bioreactor cultivation with an initial  $\text{OD}_{600}$  of 0.1. Collected aliquots were diluted in LB medium to a final volume of 100 mL before inoculation in 900 mL of SD medium for bioreactor cultivation.

#### Bioreactor cultivation

Batch and fed-batch culture experiments were conducted in a BIOSTAT® B Plus bioreactor (Sartorius Stedim, Goettingen, Germany) with two 2 L stirred tanks, filled with 1 L of SD medium each, at 37°C, pH 7.0 and supplemented with kanamycin. For pH control, 12% (v/v) ammonium hydroxide and 10% (v/v) phosphoric acid were employed. The bioreactor was equipped with two Rushton turbines and with agitation, aeration, temperature and pH controllers. A polarographic electrode was used to measure the dissolved oxygen concentration (DOC) in the culture. The  $\text{pO}_2$ , pH, stirrer speed, base and acid consumption and aeration rate were measured online and recorded by an external data acquisition and control system (Sartorius Stedim). Feeding was implemented using the bioreactor proprietary software micro-DCU system v. 0.63 (Sartorius Stedim) that allows controlling a peristaltic pump for feeding medium addition. The flow rate varied linearly from 0.066  $\text{mL min}^{-1}$  (starting after 4 h of batch culture) to 0.594  $\text{mL min}^{-1}$  after 26 h of feeding (30 h of bioreactor cultivation). In batch cultures, the DOC was maintained at 30% by cascading agitation (400–1000 rpm) with constant aeration rate (1 vvm), and the process was finished when the biomass reached stationary phase.

Fed-batch cultivations were started as batch cultures with feeding starting at 4 h of cultivation (approximately  $\text{OD}_{600\text{ nm}}$  16.0) with SD as feeding medium (see subsection "Media preparation"). Different feeding strategies were tested. In DO-stat feeding fermentations, with DOC setpoint at 30%, the agitation rate was maintained at 800 rpm (after feeding initiation). In fed-batch fermentations with a linear ascending or pH-stat feeding, the DOC was maintained at 30% by cascading agitation (400–1000 rpm) with constant aeration rate (1 vvm).

For linear ascending feeding profile we used the following equation:

$$F = at + b$$

where  $F$  is the feeding rate ( $\text{mL min}^{-1}$ ),  $t$  the cultivation time after initiation of the fed-batch culture (min) and,  $a$  and  $b$  are constants for the linear ascending feeding profile [23].

#### Analytical methods

Samples were withdrawn periodically for quantitative analysis along the cultivation. Cell growth was monitored by measuring the optical density at 600 nm ( $\text{OD}_{600\text{ nm}}$ ) in a spectrophotometer. One optical density unit was found to be equivalent to 0.3342  $\text{g L}^{-1}$  of dry cell weight by gravimetric quantitation. Glucose concentration in the medium was measured with a glucose analyzer (model 2700 select, Yellow Springs Instruments, Yellow Springs, OH, USA). Acetate concentration was determined by high performance

liquid chromatography (Äkta Purifier, GE HealthCare®, São Paulo, Brazil) equipped with an Aminex HPX-87H column (Bio-Rad Laboratories, Hercules, CA, USA), using 0.005 M H<sub>2</sub>SO<sub>4</sub> as mobile phase and a UV-detector. The protein expression was analyzed by 12% SDS-PAGE stained with Coomassie® Brilliant Blue R-250 staining. The annexin V protein produced was quantified using the Qubit® Protein Assay Kit (Invitrogen™, Life Technologies, São Paulo, SP, Brazil) and a Qubit® 2.0 Fluorometer (Invitrogen™).

#### Purification

ANXA5 recombinant protein was purified using a Fast Performance Liquid Chromatography (FPLC) ÄKTA Purifier System (GE HealthCare®). All chromatographic steps were carried out at 4°C. Sample elution was monitored by UV detection at 215, 254 and 280 nm and fractions were analyzed by 12% SDS-PAGE. According to a previous report [24], frozen cells (3 g wet weight) were suspended in 30 mL of buffer A (50 mM Tris HCl, 10 mM CaCl<sub>2</sub> pH 7.2) and incubated with 1 mM of phenylmethanesulfonyl fluoride for 30 min at 4°C. The cells were disrupted by sonication (eight pulses of 10") and centrifuged at 38,900 g for 30 min. The supernatant was discarded and the pellet was completely dissolved in 30 mL of buffer B (50 mM Tris HCl, 20 mM EDTA pH 7.2), stirred for 30 min at 4°C, and clarified by centrifugation at 38,900 g for 30 min at 4°C. The supernatant was dialyzed against 20 mM Tris HCl pH 8.0 (3 × 2 L, 3 h each). Residual precipitate was removed by centrifugation (38,900 g for 20 min) and the supernatant was loaded on a MonoQ HR 16/10 anion exchange column (GE Healthcare) previously equilibrated with 20 mM Tris HCl pH 8.0. Protein was eluted with 25% linear gradient of 20 mM Tris HCl, 1 M NaCl pH 8.0 at 1 mL min<sup>-1</sup> flow rate. Homogeneous rhANXA5 was eluted at approximately 190 mM NaCl. Fractions containing homogeneous rhANXA5 were pooled, dialyzed against 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic Acid (HEPES), 100 mM NaCl pH 7.2 and concentrated using an AMICON (Millipore Corporation, Bedford, MA, USA) ultra-filtration membrane (MWCO = 10 kDa), and stored at -80°C. Protein concentration was determined with Qubit® Protein Assay Kit using a Qubit® 2.0 Fluorometer.

#### rhANXA5 identification by mass spectrometry

rhANXA5 preparations (1 nmol) were desalted and subjected to proteolytic degradation using trypsin. The resulting peptides were separated by chromatography using 15 cm capillary columns (150 µm i.d., Kinetex C18 core-shell particles, Phenomenex, Inc., Torrance, CA, USA) and a nanoLC Ultra 1D plus equipment (Eksigent, Redwood City, CA, USA). Separated peptides were analyzed using an LTQ-Orbitrap hybrid mass spectrometer

(Thermo Fisher Scientific Inc, Waltham, MA, USA). The chromatographic method used a step gradient from mobile phase A (0.1% formic acid in water) to mobile phase B (0.1% formic acid in acetonitrile): 0–2% B over 5 min; 2–10% B over 3 min; 10–60% B over 60 min; 60–80% B over 2 min; 80% B isocratic for 10 min; 80–2% B over 2 min; and 2% B isocratic for 8 min. We performed MS/MS fragmentation using collision-induced dissociation (CID) with an activation Q of 0.250, an activation time of 30.0 ms, and an isolation width of 1.0 Da. Using the Proteome Discoverer software (v. 1.3), we compared experimentally obtained MS and MS2 spectra with the *in silico* trypsin digestion of the human proteome. We allowed a precursor tolerance of 10 ppm, a fragment tolerance of 0.8 Da, static carbamidomethylation on cysteines, and oxidation on methionine residues. We restricted our analysis to matches with an Xcorr score > 2.0 for doubly charged ions and Xcorr score > 2.5 for triply charged ions.

#### Determination of rhANXA5 molecular mass

Purified rhANXA5 samples were desalted, reconstituted in acetonitrile 50%/MilliQ-water 49%/formic acid 1% and directly injected using a 500 µL syringe (Hamilton Company, Reno, NV, USA) in a static mode into an IonMax electrospray ion source. The electrospray source parameters were as follows: positive ion mode, 4.5 kV of applied voltage to the electrospray source, 5 arbitrary units (range 0–100) of sheath gas flow, 45.6 V of capillary voltage, 250°C of capillary temperature, and 238.8 V of tube lens voltage. Full spectra (600–2000 m/z range) were collected on a Thermo Orbitrap Discovery XL in profile mode using the linear ion trap analyzer (ITMS mode). The average spectrum was processed with the software MagTran [25] for charge state deconvolution.

#### FITC-annexin V binding test

To confirm the ability of rhANXA5 to detect cells undergoing apoptosis, we labeled rhANXA5 with the FluoroTag™ FITC Conjugation Kit (Sigma-Aldrich®). Our home-made kit also contained PI solution (Sigma-Aldrich®) and a 10 × binding buffer (0.1 M HEPES-NaOH pH 7.4, 1.4 M NaCl, 25 mM CaCl<sub>2</sub>). B16F10 melanoma cells (4 × 10<sup>4</sup>), a kind gift from Dr. Peter Henson (National Jewish Center for Immunology, Denver, CO, USA) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), gentamicin 80 mg L<sup>-1</sup> (Novafarma, Anápolis, Brazil), and Fungisone 5 mg L<sup>-1</sup> (Bristol Myers Squibb, New York, NY, USA). To induce apoptosis, the cells were treated with cisplatin (Libbs, Embu, SP, Brazil) at different concentrations (0, 40, 80 and 160 µg/mL) and after 6 or 12 h, the cells were stained with our home-made kit or with a commercial kit from BD Biosciences (FITC Annexin Apoptosis Detection Kit II, BD Biosciences, San Diego, CA, USA).

Cells were stained at a concentration of  $10^5$  cells  $\text{mL}^{-1}$  in 100  $\mu\text{L}$  of 10X Binding Buffer using 5  $\mu\text{L}$  of PI and 5  $\mu\text{L}$  of rhANXA5 conjugated with FITC (home-made kit) or 5  $\mu\text{L}$  of annexin-FITC from FITC Annexin Apoptosis Detection Kit II. All data were collected in a FACSCanto II flow cytometer (BD Bioscience) and analyzed using FlowJo software (Tree Stat, San Carlos, CA, USA).

### Availability of supporting data

Supporting data are included in an additional file.

### Additional file

**Additional file 1: Figure S1.** SDS-PAGE analysis (12%) of samples from shaker cultivations of *Escherichia coli* BL21(DE3) and C41(DE3) strains in lysogeny broth (LB) and in our semi-defined (SD) media. M - Thermo Scientific™ Unstained Protein MW Marker; Lanes 1 and 5 - pET-30a(+) (empty vector) without IPTG induction; lanes 2 and 6 - pET-30a(+):ANXA5 without IPTG induction; lanes 3 and 7 - pET-30a(+) (empty vector) after 6h of IPTG induction; lane 4 - pET-30a(+):ANXA5 after 3h of IPTG induction; lane 8 - pET-30a(+):ANXA5 after 6 h of IPTG induction. **a)** C41(DE3) and LB. Overexpression of pET-30a(+):ANXA5 in *E. coli* C41(DE3) strain using LB media. **b)** BL21(DE3) and LB. Overexpression of pET-30a(+):ANXA5 in *E. coli* BL21(DE3) strain using LB media. **c)** C41(DE3) and SD. Overexpression of pET-30a(+):ANXA5 in *E. coli* C41(DE3) strain using SD media. **d)** BL21(DE3) and SD. Overexpression of pET-30a(+):ANXA5 in *E. coli* BL21(DE3) strain using SD media. **Figure S2.** Densitometric analysis of lanes 4 and 8 from Figure S1d. **Figure S3.** rhANXA5 purification in MonoQ HR16/10 column. **(a)** Eluted fractions from MonoQ HR16/10 were analysed by SDS-PAGE (12%). M corresponds to Unstained Protein MW Marker (Fermentas); Lane 1 corresponds to crude extract; Lanes 2–12 corresponds to MonoQ HR16/10 elution fractions. **(b)** Chromatogram of eluted fractions. rhANXA5 was eluted in fractions 118 to 125 (inlet). **Figure S4.** SDS-PAGE densitometric analysis of rhANXA5 expression in fed-batch cultivations. M: Thermo Scientific™ Unstained Protein MW Marker; Lanes 1–3: samples collected at 30 h of culture (triplicate). rhANXA5 corresponded to (1) 45.3%, (2) 38.6% and (3) 37.9% of total protein content.

### Abbreviations

DOC: Dissolved oxygen concentration; FITC: Fluorescein isothiocyanate; HEPES: Hydroxyethylpiperazine-N'-2-ethanesulfonic acid; LB: Lysogeny broth; MCB: Master cell bank; PI: Propidium iodide; PS: Phosphatidylserine; rhANXA5: Recombinant human annexin V; TB: Terrific broth.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

LSM carried out part of the experiments and contributed to the manuscript writing. JL carried out part of the experiments and contributed to the manuscript writing. GR helped in fermentation and protein purification. DCR helped in cloning, amplification and purification. GOP generated the FITC-rhANXA5. JESN assisted in the production of rhANXA5 in the bioreactor. APDS conducted the FITC-annexin V binding experiments. ACOD helped in cloning and expression. CVB performed the identification and molecular mass determination of rhANXA5 by mass spectrometry and contributed to the manuscript writing. JMC and LAB assisted in most of the experiments and DSS devised the experiments. All authors read and approved the final manuscript.

### Acknowledgements

Financial support for this work was provided by the National Institute of Science and Technology on Tuberculosis (Decit/SCTIE/MS-MCT-CNPq-FNDCT-CAPES) and Millennium Initiative Program (CNPq), Brazil to DS and LB. DS (CNPq, 304051/1975-06) and LB (CNPq, 5201182/99-5) are research career

awardees of the National Council for Scientific and Technological Development of Brazil.

### Author details

<sup>1</sup>Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga 6681, 90619-900 Porto Alegre, Brazil. <sup>2</sup>Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre 90619-900, Brazil. <sup>3</sup>Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Porto Alegre 90619-900, Brazil. <sup>4</sup>Quatro G Pesquisa & Desenvolvimento, LTDA, Porto Alegre 90619-900, Brazil. <sup>5</sup>Instituto de Pesquisas Biomédicas (IPB), Laboratório de Imunologia Molecular, PUCRS, Porto Alegre 90619-900, Brazil.

Received: 5 August 2013 Accepted: 11 April 2014

Published: 27 April 2014

### References

1. Crompton MR, Moss SE, Crompton MJ: Diversity in the Lipocortin/Calpactin Family. *Cell* 1988, **55**:1–3.
2. Schick PK, Kurica KB, Chacko GK: Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane. *J Clin Invest* 1976, **57**:1221–1226.
3. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. *J Immunol* 1992, **148**(7):2207–2216.
4. Tait JF, Gibson D, Fujikawa K: Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. *J Biol Chem* 1989, **264**(14):7944–7949.
5. Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens ET, Willems GM: Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. *J Biol Chem* 1990, **265**(9):4923–4928.
6. Blankenberg FG, Tait JF, Strauss HW: Apoptotic cell death: its implications for imaging in the next millennium. *Eur J Nucl Med* 2000, **27**(3):359–367.
7. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. *J Immunol Methods* 1995, **184**:39–51.
8. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G: Apoptosis-detecting radioligands: current state of the art and future perspectives. *Eur J Nucl Med Mol Imaging* 2004, **31**:887–919.
9. Yang DJ, Azhdarinia A, Wu P, Yu DF, Tansey W, Kalimi SK, Kim EE, Podoloff DA: In Vivo and In Vitro Measurement of Apoptosis in Breast Cancer Cells Using <sup>99m</sup>Tc-EC-Annexin V. *Cancer Biother Radiopharm* 2001, **16**:73–83.
10. Brumatti G, Sheridan C, Martin SJ: Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells. *Methods* 2008, **44**:235–240.
11. Logue SE, Elgendy M, Martin SJ: Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. *Nat Protoc* 2009, **4**:1383–1395.
12. Coxon KM, Duggan J, Cordeiro MF, Moss SE: Purification of annexin V and its use in the detection of apoptotic cells. *Methods Mol Biol* 2011, **731**:293–308.
13. Wang F, He XW, Yan HL, Huang JJ, Zhang Y, Jiang L, Gao YJ, Sun SH: Non-fusion expression in *Escherichia coli*: Single-step purification of recombinant human annexin A5 for detection of apoptosis. *Protein Expr Purif* 2006, **45**:80–87.
14. Lee SY: High cell-density culture of *Escherichia coli*. *Trends Biotechnol* 1996, **14**:98–105.
15. Krause M, Ukkonen K, Haataja T, Ruottinen M, Glumoff T, Neubauer A, Neubauer P, Vasala A: A novel fed-batch based cultivation method provides high cell-density and improves yield of soluble recombinant protein in shaken cultures. *Microb Cell Fact* 2010, **9**:1–11.
16. Kim BS, Lee SC, Lee SY, Chang YK, Chang HN: High cell density fed-batch cultivation of *Escherichia coli* using exponential feeding combined with pH-stat. *Bioprocess Biosyst Eng* 2004, **26**:147–150.
17. Luli GW, Strohl WR: Comparison of growth, acetate production, and acetate inhibition of *Escherichia coli* strains in batch and fed-batch fermentations. *Appl Environ Microbiol* 1990, **56**:1004–1011.



18. The National Center for Biotechnology Information (NCBI) - ANXA5 annexin A5 (*Homo sapiens* human). [<http://www.ncbi.nlm.nih.gov/gene/308>].
19. Yuan H, Yang X, Hua Z-C: Optimization of expression of an Annexin V-Hirudin chimeric protein in *Escherichia coli*. *Microbiol Res* 2004, **159**:147–156.
20. Choi JH, Keum KC, Lee SY: Production of recombinant proteins by high cell density culture of *Escherichia coli*. *Chemical Engineering Science* 2006, **61**:876–885.
21. Roth G, Nunes JES, Rosado LA, Bizarro CV, Volpato G, Nunes CP, Renard G, Basso LA, Santos DS, Chies JM: Recombinant *Erwinia carotovora* l-asparaginase II production in *Escherichia coli* fed-batch cultures. *Braz J Chem Eng* 2013, **30**(2):245–256.
22. Sambrook J, Russell DW: *Molecular Cloning: A Laboratory Manual*. 3rd edition. New York: CSHL Press; 2001:159–174.
23. Ayub MAZ: Fed-batch bioreactor process with recombinant *Saccharomyces cerevisiae* growing on cheese whey. *Braz J Chem Eng* 2006, **23**(4):435–442.
24. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. *Blood* 1996, **88**:1873–1880.
25. Zhang Z, Marshall AG: A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. *J Am Chem Soc Mass Spectrom* 1998, **9**:225–233.

doi:10.1186/1472-6750-14-33

Cite this article as: Marder *et al.*: Production of recombinant human annexin V by fed-batch cultivation. *BMC Biotechnology* 2014 **14**:33.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

